AG
APLS

Aperio Group’s Apellis Pharmaceuticals APLS Stock Holding History

Aperio Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$235K Buy
+4,113
New +$174K ﹤0.01% 2263
2019
Q3 		– Sell
-77
Closed -$2K – 2327
2019
Q2 		$2K Buy
+77
New +$1.57K ﹤0.01% 2918

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Aperio Group's APLS Position: Q4 2020 in Review

Aperio Group opened a new position in Apellis Pharmaceuticals (APLS) in Q4 2020: 4,113 shares worth $235K. The stake represents ﹤0.01% of the portfolio and ranks #2263 among its holdings. This is a return to the name: Aperio Group previously reported a position in APLS as recently as Q2 2019.

Aperio Group first reported a position in APLS in Q2 2019 and has held it in 2 quarters since. 168 funds tracked by Wall St. Rank hold APLS as of Q4 2020.

  • Aperio Group held 4,113 shares of Apellis Pharmaceuticals worth $235K as of Q4 2020.
  • Apellis Pharmaceuticals was a new Aperio Group position in Q4 2020.
  • Apellis Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2263 holding.
  • Aperio Group first reported a position in Apellis Pharmaceuticals in Q2 2019 and has held it in 2 quarters since.
  • 168 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.